Age-related maculopathy: pathogenetic features and new treatment modalities
Article first published online: 12 MAR 2003
Acta Ophthalmologica Scandinavica
Volume 80, Issue 2, pages 136–143, April 2002
How to Cite
Algvere, P. V. and Seregard, S. (2002), Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmologica Scandinavica, 80: 136–143. doi: 10.1034/j.1600-0420.2002.800204.x
- Issue published online: 12 MAR 2003
- Article first published online: 12 MAR 2003
- Received on November 28th, 2001.Accepted on January 17th, 2002.
- age-related maculopathy;
- age-related macular degeneration;
- oxidative stress;
- free radicals;
- photodynamic therapy (PDT);
- transpupillary thermotherapy (TTT)
A considerable amount of new information on putative pathogenetic mechanisms in age-related maculopathy and degeneration has emerged in recent years. This comprises experimental studies on retinal pigment epithelium (RPE) and rod photoreceptor ageing, lipofuscin accumulation, the roles of oxidative stress and free radical formation, as well as antioxidants and other defensive mechanisms operating against environmental factors and ageing.
The current application of photodynamic therapy (PDT) using verteporfin marks a new era in the treatment of subfoveal classical choroidal neovascularization. Several new treatment modalities, such as transpupillary thermotherapy (TTT) and anti-vascular endothelial growth factor (VEGF) agents for inhibition of neovascularization, have emerged and are undergoing multicentre clinical trials. A period of dynamic development in this field has commenced.